{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:12:05Z","timestamp":1789708325719,"version":"4.0.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bruton tyrosine kinase (BTK) is essential for B-cell receptor (BCR) signaling, a driver of chronic lymphocytic leukemia (CLL). Covalent inhibitors bind C481 in the active site of BTK and have become a preferred CLL therapy. Disease progression on covalent BTK inhibitors is commonly associated with C481 mutations. Here, we investigated a targeted protein degrader, NRX-0492, that links a noncovalent BTK-binding domain to cereblon, an adaptor protein of the E3 ubiquitin ligase complex. NRX-0492 selectively catalyzes ubiquitylation and proteasomal degradation of BTK. In primary CLL cells, NRX-0492 induced rapid and sustained degradation of both wild-type and C481 mutant BTK at half maximal degradation concentration (DC50) of \u22640.2 nM and DC90 of \u22640.5 nM, respectively. Sustained degrader activity was maintained for at least 24 hours after washout and was equally observed in high-risk (deletion 17p) and standard-risk (deletion 13q only) CLL subtypes. In in\u00a0vitro testing against treatment-na\u00efve CLL samples, NRX-0492 was as effective as ibrutinib at inhibiting BCR-mediated signaling, transcriptional programs, and chemokine secretion. In patient-derived xenografts, orally administered NRX-0492 induced BTK degradation and inhibited activation and proliferation of CLL cells in blood and spleen and remained efficacious against primary C481S mutant CLL cells collected from a patient progressing on ibrutinib. Oral bioavailability, &amp;gt;90% degradation of BTK at subnanomolar concentrations, and sustained pharmacodynamic effects after drug clearance make this class of targeted protein degraders uniquely suitable for clinical translation, in particular as a strategy to overcome BTK inhibitor resistance. Clinical studies testing this approach have been initiated (NCT04830137, NCT05131022).<\/jats:p>","DOI":"10.1182\/blood.2022016934","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:05:19Z","timestamp":1668441919000},"page":"1584-1596","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in\u00a0vivo activity in CLL patient-derived xenografts"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1581-2357","authenticated-orcid":false,"given":"Deyi","family":"Zhang","sequence":"first","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-3037","authenticated-orcid":false,"given":"Hailey M.","family":"Harris","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-0061","authenticated-orcid":false,"given":"Jonathan","family":"Chen","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2246-9745","authenticated-orcid":false,"given":"Jen","family":"Judy","sequence":"additional","affiliation":[{"name":"2Bioinformatics Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"James","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Kelly","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"McIntosh","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Tenn-McClellan","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Ambing","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Siow","family":"Tan","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lu","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5432-0403","authenticated-orcid":false,"given":"Stefan","family":"Gajewski","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Clifton","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Yung","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Robbins","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4210-6458","authenticated-orcid":false,"given":"Mehdi","family":"Pirooznia","sequence":"additional","affiliation":[{"name":"2Bioinformatics Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid S.","family":"Sk\u00e5nland","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"},{"name":"4Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway"},{"name":"5K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4831-3105","authenticated-orcid":false,"given":"Erika","family":"Gaglione","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maissa","family":"Mhibik","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1566-7337","authenticated-orcid":false,"given":"Chingiz","family":"Underbayev","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-4729","authenticated-orcid":false,"given":"Clare","family":"Sun","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E. M.","family":"Herman","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-1059","authenticated-orcid":false,"given":"Mark","family":"Noviski","sequence":"additional","affiliation":[{"name":"3Nurix Therapeutics, Inc, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2023110216012768200_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023110216012768200_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-\u03baB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2023110216012768200_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"issue":"16","key":"2023110216012768200_bib4","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2023110216012768200_bib5","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"IBR in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2023110216012768200_bib6","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable IBR responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2023110216012768200_bib7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with IBR: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"2023110216012768200_bib8","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of IBR with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"issue":"18","key":"2023110216012768200_bib9","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"issue":"10232","key":"2023110216012768200_bib10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"2023110216012768200_bib11","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton tyrosine kinase inhibitor IBR (PCI-32765)","volume":"54","author":"Burger","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2023110216012768200_bib12","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"IBR inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023110216012768200_bib13","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with IBR targeted therapy","volume":"8","author":"Landau","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2023110216012768200_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2023110216012768200_bib15","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to IBR in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2023110216012768200_bib16","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"IBR as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023110216012768200_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"IBR versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023110216012768200_bib18","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"IBR for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023110216012768200_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"IBR-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023110216012768200_bib20","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"IBR regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023110216012768200_bib21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line IBR treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2023110216012768200_bib22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"IBR for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023110216012768200_bib23","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to IBR resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2023110216012768200_bib24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to IBR in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023110216012768200_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with IBR-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2023110216012768200_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, gamma2 acquired in IBR-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2023110216012768200_bib27","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor IBR","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023110216012768200_bib28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2021","journal-title":"Haematologica"},{"issue":"10277","key":"2023110216012768200_bib29","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"Supplement 1","key":"2023110216012768200_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2021-148672","article-title":"Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: A phase 2 dose expansion study","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023110216012768200_bib31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2023110216012768200_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.37349\/etat.2020.00009","article-title":"Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors","volume":"1","author":"Arthur","year":"2020","journal-title":"Explor Target Antitumor Ther"},{"issue":"8","key":"2023110216012768200_bib33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in\u00a0vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"Supplement_1","key":"2023110216012768200_bib34","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1182\/blood-2019-129262","article-title":"Targeted protein degradation of BTK as a unique therapeutic approach for B cell malignancies","volume":"134","author":"Kelly","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"2023110216012768200_bib35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/annrheumdis-2021-eular.1675","article-title":"POS0006 NX-5948, A selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease","volume":"80","author":"Robbins","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"Supplement 1","key":"2023110216012768200_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-141461","article-title":"Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies","volume":"136","author":"Robbins","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2023110216012768200_bib37","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.leukres.2006.05.003","article-title":"Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors","volume":"30","author":"Tohda","year":"2006","journal-title":"Leuk Res"},{"issue":"12","key":"2023110216012768200_bib38","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2013.131","article-title":"Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy","volume":"27","author":"Herman","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2023110216012768200_bib39","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"2023110216012768200_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem Biol"},{"issue":"3","key":"2023110216012768200_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12185-016-2073-4","article-title":"Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs","volume":"104","author":"Ito","year":"2016","journal-title":"Int J Hematol"},{"issue":"6168","key":"2023110216012768200_bib42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"7611","key":"2023110216012768200_bib43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A\u00a0novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"6","key":"2023110216012768200_bib44","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","article-title":"Impact of genetic polymorphisms on human immune cell gene expression","volume":"175","author":"Schmiedel","year":"2018","journal-title":"Cell"},{"issue":"4","key":"2023110216012768200_bib45","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.18632\/oncotarget.6727","article-title":"Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to IBR","volume":"7","author":"Guo","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"2023110216012768200_bib46","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2023110216012768200_bib47","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"20","key":"2023110216012768200_bib48","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A\u00a0novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2023110216012768200_bib49","doi-asserted-by":"crossref","first-page":"e86288","DOI":"10.1172\/jci.insight.86288","article-title":"Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process","volume":"1","author":"Patten","year":"2016","journal-title":"JCI Insight"},{"key":"2023110216012768200_bib50","doi-asserted-by":"crossref","first-page":"627020","DOI":"10.3389\/fimmu.2021.627020","article-title":"A\u00a0detailed analysis of parameters supporting the engraftment and growth of chronic lymphocytic leukemia cells in immune-deficient mice","volume":"12","author":"Patten","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"2023110216012768200_bib51","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023110216012768200_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A\u00a0chemoproteomic approach to query the degradable kinome using a multi-kinase degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"9","key":"2023110216012768200_bib53","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","volume":"133","author":"Dobrovolsky","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023110216012768200_bib54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","article-title":"Targeted protein degraders crowd into the clinic","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2023110216012768200_bib55","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","article-title":"CCL3\u00a0(MIP-1alpha) plasma levels and the risk\u00a0for disease progression in chronic lymphocytic leukemia","volume":"117","author":"Sivina","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2023110216012768200_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12867","article-title":"The Bruton tyrosine kinase inhibitor IBR (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach","volume":"166","author":"Sivina","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/13\/1584\/2087864\/blood_bld-2022-016934-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/13\/1584\/2087864\/blood_bld-2022-016934-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:02:12Z","timestamp":1698926532000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/13\/1584\/487108\/NRX-0492-degrades-wild-type-and-C481-mutant-BTK"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":56,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,3,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016934","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}